Milrinone versus dobutamine: contribution of altered myocardial mechanics and augmented inotropic state to improved left ventricular performance.
Milrinone and dobutamine are positive inotropic agents with complex mechanisms of action. Traditional indexes of left ventricular function are unable to determine how much of the improvement in cardiac performance induced by these drugs is due to augmented inotropy and how much is the result of afterload reduction. Recently, the end-systolic wall stress (sigma es)-rate corrected velocity of fiber shortening (Vcfc) relationship has been shown to be a sensitive measure of contractility that is independent of preload while incorporating afterload. This index was measured in two groups of normal subjects (n = 8 per group) over a wide range of aortic pressures generated by administration of methoxamine before and during (1) milrinone or (2) dobutamine infusion. Studies were performed with the use of echocardiographic and calibrated carotid pulse tracings. Milrinone and dobutamine produced similar increases in overall left ventricular performance. Milrinone decrease end-systolic dimension (Des) by 15% and end-systolic pressure (Pes) by 22%, while increasing end-systolic wall thickness (hes) by 14%. This resulted in a 43% decline in left ventricular afterload as measured by sigma es. In contrast, dobutamine decreased Des by 11% while increasing hes by 14% and Pes by 22%. Despite the increase in left ventricular pressure, sigma es fell by 20%. Since afterload reduction alone results in increased left ventricular shortening, analysis of left ventricular performance was performed for both drugs at matched levels of sigma es under control and positive inotropic conditions. Twenty-nine percent of the improvement in Vcfc produced by milrinone was due to a decrease in afterload as compared with 18% of that produced by dobutamine.(ABSTRACT TRUNCATED AT 250 WORDS)
D000328:Adult; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004280:Dobutamine / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D020105:Milrinone; D009200:Myocardial Contraction / Q000187:drug effects*; D011728:Pyridones / Q000494:pharmacology*; D013997:Time Factors
D002316:Cardiotonic Agents; D011728:Pyridones; D004280:Dobutamine; D020105:Milrinone